Oludotun A. Phillips

Safat, KU 13060, Kuwait

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Validated LC-MS/MS Assays for Novel Triazolyl-Oxazolidinones with Anticonvulsant Activities and Their Potential Applications in Stability and Pharmacokinetic Studies.

Validated LC-MS/MS Assays for Novel Triazolyl-Oxazolidinones with Anticonvulsant Activities and Their Potential Applications in Stability and Pharmacokinetic Studies.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: May 12, 2026

In vivo antiseizure activity of triazolyl oxazolidinone derivatives in rats.

In vivo antiseizure activity of triazolyl oxazolidinone derivatives in rats.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: February 01, 2026

Stability-Indicating Assay of Novel 5-(Hydroxamic acid)methyl Oxazolidinones with 5-Lipooxygenase Inhibitory Activity.

Stability-Indicating Assay of Novel 5-(Hydroxamic acid)methyl Oxazolidinones with 5-Lipooxygenase Inhibitory Activity.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: July 29, 2025

Development and Validation of Stability-Indicating Assay Method for a Novel Oxazolidinone (PH-192) with Anticonvulsant Activity by Using UHPLC-QToF-MS.

Development and Validation of Stability-Indicating Assay Method for a Novel Oxazolidinone (PH-192) with Anticonvulsant Activity by Using UHPLC-QToF-MS.

Journal: Molecules (Basel, Switzerland)
Published: December 30, 2021

Anti-allergic, anti-asthmatic and anti-inflammatory effects of an oxazolidinone hydroxamic acid derivative (PH-251) - A novel dual inhibitor of 5-lipoxygenase and mast cell degranulation.

Anti-allergic, anti-asthmatic and anti-inflammatory effects of an oxazolidinone hydroxamic acid derivative (PH-251) - A novel dual inhibitor of 5-lipoxygenase and mast cell degranulation.

Journal: International immunopharmacology
Published: August 23, 2021

GYY4137 attenuates functional impairment of corpus cavernosum and reduces fibrosis in rats with STZ-induced diabetes by inhibiting the TGF-β1/Smad/CTGF pathway.

GYY4137 attenuates functional impairment of corpus cavernosum and reduces fibrosis in rats with STZ-induced diabetes by inhibiting the TGF-β1/Smad/CTGF pathway.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: December 28, 2020

Synthesis and structure-activity relationships of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives as 5-lipoxygenase inhibitors.

Synthesis and structure-activity relationships of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives as 5-lipoxygenase inhibitors.

Journal: Journal of enzyme inhibition and medicinal chemistry
Published: July 09, 2020

Anti-progressive Effects of a Series of Glycinyl and Alaninyl Triazolyl-oxazolidinones on Kelly Neuroblastoma Cell Line.

Anti-progressive Effects of a Series of Glycinyl and Alaninyl Triazolyl-oxazolidinones on Kelly Neuroblastoma Cell Line.

Journal: Anticancer research
Published: June 15, 2020

H2S donor GYY4137 ameliorates paclitaxel-induced neuropathic pain in mice.

H2S donor GYY4137 ameliorates paclitaxel-induced neuropathic pain in mice.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: February 16, 2020

A novel oxazolidinone derivative PH192 demonstrates anticonvulsant activity in vivo in rats and mice.

A novel oxazolidinone derivative PH192 demonstrates anticonvulsant activity in vivo in rats and mice.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: October 01, 2018

Structure-Antibacterial Activity Relationships of N-Substituted-(d-/l-Alaninyl) 1H-1,2,3-Triazolylmethyl Oxazolidinones.

Structure-Antibacterial Activity Relationships of N-Substituted-(d-/l-Alaninyl) 1H-1,2,3-Triazolylmethyl Oxazolidinones.

Journal: Scientia pharmaceutica
Published: August 30, 2018

Alleviation of impaired reactivity in the corpus cavernosum of STZ-diabetic rats by slow-release H2S donor GYY4137.

Alleviation of impaired reactivity in the corpus cavernosum of STZ-diabetic rats by slow-release H2S donor GYY4137.

Journal: International journal of impotence research
Published: October 10, 2017
Showing 1-12 of 25

Last Updated: 09/26/2026